MSD has initiated a new Phase 2 clinical trial to evaluate opevesostat (MK-5684) in women's cancers, expanding beyond its current prostate cancer program.
A Phase 3 trial (MK-5684-003) is underway to evaluate opevesostat, a CYP11A1 inhibitor, against next-generation hormonal agent (NHA) switch in mCRPC patients after NHA and taxane-based chemotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.